参考文献/References:
[1] Junttila IS. Tuning the cytokine responses:an update on interleukin (IL)-4 and IL-13 receptor complexes[J]. Front Immunol,2018,9:888.[2]Iwaszko M,Bialy S,Bogunia-Kubik K.Significance of interleukin(IL)-4 and IL-13 in inflammatory arthritis[J]. Cells,2021,10(11):3000.[3]Nur Husna SM,Md Shukri N,Mohd Ashari NS,et al. IL-4/IL-13 axis astherapeutic targets in allergic rhinitis and asthma[J]. Peer J,2022,10:e13444.[4] Farahi L,Sinha SK,Lusis AJ. Roles of macrophages in atherogenesis[J]. Front Pharmacol,2021,12:785220.[5] Barrett TJ. Macrophages in atherosclerosis regression[J]. Arterioscler Thromb Vasc Biol,2020,40(1):20-33.[6] Runtsch MC,Angiari S,Hooftman A,et al. Itaconate and itaconate derivatives target JAK1 to suppress alternative activation of macrophages[J]. Cell Metab,2022,34(3):487-501.[7] 贺玲,吕坤.巨噬细胞极化在心血管疾病中的作用[J].国际免疫学杂志,2016,39(2):168-171.[8] Cardilo-Reis L,Gruber S,Schreier SM,et al. Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype[J]. EMBO Mol Med,2012,4(10):1072-1086.[9]Munjal A,Khandia R. Atherosclerosis:orchestrating cells and biomolecules involved in its activation and inhibition[J]. Adv Protein Chem Struct Biol,2020,120:85-122.[10] Wang J,Liu M,Wu Q,et al. Human embryonic stem cell-derived cardiovascular progenitors repair infarcted hearts through modulation of macrophages via activation of signal transducer and activator of transcription 6[J]. Antioxid Redox Signal,2019,31(5):369-386.[11]Weinstock A,Rahman K,Yaacov O,et al. Wnt signaling enhances macrophage responses to IL-4 and promotes resolution of atherosclerosis[J]. Elife,2021,10:e67932. [12] Zhang Y,Zhang M,Li X,et al. Silencing microRNA-155 attenuates cardiac injury and dysfunction in viral myocarditis via promotion of M2 phenotype polarization of macrophages[J]. Sci Rep,2016,6:22613.[13] Yang H,Chen Y,Gao C. Interleukin-13 reduces cardiac injury and prevents heart dysfunction in viral myocarditis via enhanced M2 macrophagepolarization[J].Oncotarget,2017,8(59):99495-99503.[14] Gao S,Zhou J,Liu N,et al. Curcumin induces M2 macrophage polarization by secretion IL-4 and/or IL-13[J]. J Mol Cell Cardiol,2015,85:131-139. [15] Cihakova D,Barin JG,Afanasyeva M,et al. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation[J]. Am J Pathol,2008,172(5):1195-1208. [16] Segiet OA,Piecuch A,Mielanczyk L,et al. Role of interleukins in heart failure with reduced ejection fraction[J]. Anatol J Cardiol,2019,22(6):287-299.[17] Nishimura Y,Inoue T,Nitto T,et al. Increased interleukin-13 levels in patients with chronic heart failure[J]. Int J Cardiol,2009,131(3):421-423. [18] Amit U,Kain D,Wagner A,et al. New role for interleukin-13 receptor α1 in myocardial homeostasis and heart failure[J]. J Am Heart Assoc,2017,6(5):e005108.[19]Karo-Atar D,Bordowitz A,Wand O,et al. A protective role for IL-13 receptor α1 in bleomycin-induced pulmonary injury and repair[J]. Mucosal Immunol,2016,9(1):240-253. [20]She G,Ren YJ,Wang Y,et al. KCa3.1 channels promote cardiac fibrosis through mediating inflammation and differentiation of monocytes into myofibroblasts in angiotensinⅡ-treated rats[J]. Am Heart Assoc,2019,8(1):e010418. [21] Sheikh F,Dickensheets H,Pedras-Vasconcelos J,et al. The interleukin-13 receptor-α1 chain is essential for induction of the alternative macrophage activation pathway by IL-13 but not IL-4[J]. Innate Immun,2015,7(5):494-505.[22]Nishimura Y,Inoue T,Morooka T,et al. Mechanical stretch and angiotensinⅡ increase interleukin-13 production and interleukin-13 receptor alpha2 expression in rat neonatal cardiomyocytes[J]. Circ J,2008,72(4):647-653. [23] Amir O,Spivak I,Lavi I,et al. Changes in the monocytic subsets CD14dimCD16+ and CD14++CD16- in chronic systolic heart failure patients[J]. Mediators Inflamm,2012,2012:616384.[24] Hofmann U,Beyersdorf N,Weirather J,et al. Activation of CD4+ T lymphocytes improves wound healing and survival after experimental myocardial infarction in mice[J].Circulation,2012,125(13):1652-1663.[25] Bakhshian Nik A,Alvarez-Argote S,O’Meara CC. Interleukin 4/13 signaling in cardiac regeneration and repair[J]. Am J Physiol Heart Circ Physiol,2022,323(5):H833-H844.[26] Hofmann U,Knorr S,Vogel B,et al.Interleukin-13 deficiency aggravates healing and remodeling in male mice after experimental myocardial infarction[J]. Circ Heart Fail,2014,7(5):822-830.[27] Boag SE,Andreano E,Spyridopoulos I. Lymphocyte communication in myocardial ischemia/reperfusion injury[J]. Antioxid Redox Signal,2017,26(12):660-675.[28] Yuan D,Tie J,Xu Z,et al. Dynamic profile of CD4+ T-cell-associated cytokines/chemokines following murine myocardial infarction/reperfusion[J]. Mediators Inflamm,2019,2019:9483647.[29] Kumar V,Prabhu SD,Bansal SS. CD4+ T-lymphocytes exhibit biphasic kinetics post-myocardial infarction[J]. Front Cardiovasc Med,2022,9:992653.[30] Yuan L,Chen X,Cheng L,et al. HDAC11 regulates interleukin-13 expression in CD4+ T cellsin the heart[J]. J Mol Cell Cardiol,2018,122:1-10.[31] Skapenko A,Kalden JR,Lipsky PE,et al. The IL-4 receptor alpha-chain-binding cytokines,IL-4 and IL-13,induce forkhead box P3-expressing CD25+CD4+ regulatory T cells from CD25－CD4+ precursors[J]. J Immunol,2005,175(9):6107-6116.[32] Mora-Ruíz MD,Blanco-Favela F,Chávez Rueda AK,et al. Role of interleukin-17 in acute myocardial infarction[J]. Mol Immunol,2019,107:71-78.[33] Belpaire A,van Geel N,Speeckaert R. From IL-17 to IFN-γ in inflammatory skin disorders:is transdifferentiation a potential treatment target[J]. FrontImmunol,2022,13:932265.[34] Newcomb DC,Zhou W,Moore ML,et al. A functional IL-13 receptor is expressed on polarized murine CD4+ Th17 cells and IL-13 signaling attenuates Th17 cytokine production[J]. Immunol,2009,182(9):5317-5321.[35] Uchida AM,Ro G,Qiang L,et al. Human differentiated eosinophils release IL-13 in response to IL-33 stimulation[J]. Front Immunol,2022,13:946643.[36] Liu J,Yang C,Liu T,et al. Eosinophils improve cardiac function after myocardial infarction[J]. Nat Commun,2020,11(1):6396.[37] Xu JY,Xiong YY,Tang RJ,et al.Interleukin-5-induced eosinophil population improves cardiac function after myocardial infarction[J]. Cardiovasc Res,2022,118(9):2165-2178.[38] Diny NL,Baldeviano GC,Talor MV,et al. Eosinophil-derived IL-4 drives progression of myocarditis to inflammatory dilated cardiomyopathy[J]. J Exp Med,2017,214(4):943-957.[39] Golino M,Moroni F,Del Buono MG,et al. Change in eosinophil count in patients with heart failure treated with anakinra[J]. Cells,2023,12(8):1129.[40] Maspero J,Adir Y,Al-Ahmad M,et al. Type 2 inflammation in asthma and other airway diseases[J]. ERJ Open Res,2022,8(3):00576-02021.[41] Zhong Z,Yang Z,Peng Y,et al. Diagnosis and treatment of eosinophilic myocarditis[J]. J Transl Autoimmun,2021,4:100118. [42] Diny NL,Hou X,Barin JG,et al. Macrophages and cardiac fibroblasts are the main producers of eotaxins and regulate eosinophil trafficking to the heart[J]. Eur J Immunol,2016,46(12):2749-2760.